- Home
- SEZL vs SDGR Comparison
SEZL vs SDGR Comparison
Compare SEZL & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEZL
- SDGR
- Stock Information
- Founded
- SEZL 2016
- SDGR 1990
- Country
- SEZL United States
- SDGR United States
- Employees
- SEZL N/A
- SDGR N/A
- Industry
- SEZL Diversified Financial Services
- SDGR Biotechnology: Pharmaceutical Preparations
- Sector
- SEZL Finance
- SDGR Health Care
- Exchange
- SEZL Nasdaq
- SDGR Nasdaq
- Market Cap
- SEZL N/A
- SDGR 1.8B
- IPO Year
- SEZL N/A
- SDGR 2020
- Fundamental
- Price
- SEZL $28.70
- SDGR $18.16
- Analyst Decision
- SEZL Strong Buy
- SDGR Buy
- Analyst Count
- SEZL 2
- SDGR 7
- Target Price
- SEZL $61.42
- SDGR $32.29
- AVG Volume (30 Days)
- SEZL 841.1K
- SDGR 907.7K
- Earning Date
- SEZL 05-07-2025
- SDGR 04-30-2025
- Dividend Yield
- SEZL N/A
- SDGR N/A
- EPS Growth
- SEZL 950.56
- SDGR N/A
- EPS
- SEZL 2.19
- SDGR N/A
- Revenue
- SEZL $271,127,890.00
- SDGR $207,539,000.00
- Revenue This Year
- SEZL $33.01
- SDGR $24.42
- Revenue Next Year
- SEZL $16.24
- SDGR $19.02
- P/E Ratio
- SEZL $13.12
- SDGR N/A
- Revenue Growth
- SEZL 70.14
- SDGR N/A
- 52 Week Low
- SEZL $6.73
- SDGR $16.67
- 52 Week High
- SEZL $79.59
- SDGR $29.15
- Technical
- Relative Strength Index (RSI)
- SEZL 32.82
- SDGR 37.33
- Support Level
- SEZL $32.50
- SDGR $21.34
- Resistance Level
- SEZL $37.84
- SDGR $20.21
- Average True Range (ATR)
- SEZL 3.26
- SDGR 1.06
- MACD
- SEZL -0.64
- SDGR -0.28
- Stochastic Oscillator
- SEZL 20.24
- SDGR 11.75
Stock Price Comparison Chart: SEZL vs SDGR
■ SEZL
■ SDGR
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
Share on Social Networks:
0